$-0.27 EPS Expected for Celsion Corporation (CLSN)

July 14, 2018 - By Vernon Prom

Celsion Corporation (NASDAQ:CLSN) Logo

Analysts expect Celsion Corporation (NASDAQ:CLSN) to report $-0.27 EPS on August, 13.They anticipate $0.52 EPS change or 65.82 % from last quarter’s $-0.79 EPS. After having $-0.25 EPS previously, Celsion Corporation’s analysts see 8.00 % EPS growth. The stock increased 0.33% or $0.01 during the last trading session, reaching $3.06. About 150,673 shares traded. Celsion Corporation (NASDAQ:CLSN) has declined 25.52% since July 14, 2017 and is downtrending. It has underperformed by 38.09% the S&P500.

Celsion Corporation, an oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The company has market cap of $54.02 million. The company's lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials for recurrent chest wall breast cancer. It currently has negative earnings. It is also developing GEN-1, a DNA immunotherapeutic product for the localized treatment of ovarian and brain cancers.

More notable recent Celsion Corporation (NASDAQ:CLSN) news were published by: Benzinga.com which released: “38 Stocks Moving In Tuesday’s Mid-Day Session” on June 19, 2018, also Benzinga.com with their article: “The Week Ahead In Biotech: Delayed Clinical Trial Releases In Focus” published on June 30, 2018, Globenewswire.com published: “Celsion Corporation Announces Strategic Loan Facility” on June 28, 2018. More interesting news about Celsion Corporation (NASDAQ:CLSN) were released by: Streetinsider.com and their article: “Celsion (CLSN) Reports Publication of Thermodox Phase I Clinical Study Results in the Lancet Oncology” published on July 10, 2018 as well as Benzinga.com‘s news article titled: “48 Biggest Movers From Yesterday” with publication date: June 20, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.